Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7925918 | 1.00 | KMT2A (0.40) | KMT2AMEN1MAPK1APLNRDPP8 | |
| SCHEMBL22644339 | 0.83 | APLNR (0.40) | KMT2AMEN1MAPK1APLNRDPP8 | |
| SCHEMBL6884925 | 0.83 | KMT2A (0.39) | KMT2AMEN1MAPK1APLNRDPP8 | |
| SCHEMBL56916 | 0.81 | TDP1 (0.41) | KMT2AMEN1MAPK1APLNRTDP1 | |
| SCHEMBL6887591 | 0.79 | APLNR (0.37) | KMT2AMEN1MAPK1APLNRDPP8 | |
| SCHEMBL5521873 | 0.78 | P2RX7 (0.42) | KMT2AMEN1MAPK1APLNRTDP1 | |
| SCHEMBL1368840 | 0.78 | P2RX7 (0.40) | KMT2AMEN1MAPK1APLNRTDP1 | |
| SCHEMBL22380561 | 0.77 | MEN1 (0.35) | KMT2AMEN1MAPK1TDP1CACNA1H | |
| SCHEMBL12975362 | 0.77 | P2RX7 (0.44) | KMT2AMEN1MAPK1APLNRTDP1 | |
| SCHEMBL941564 | 0.77 | P2RX7 (0.44) | KMT2AMEN1MAPK1APLNRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582660-B1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD | 2015-01-22 | — | — | US | disclosed |
| US-8859505-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2509956-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752404-A1 | Cysteine protease inhibitors | Medivir UK Ltd (GB) | 2014-07-09 | — | — | EP | disclosed |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2013-07-04 | — | — | US | disclosed |
| WO-2012172473-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012168852-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-13 | — | — | WO | disclosed |
| WO-2011158197-A1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011070539-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070541-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | KMT2A 2611/4885MEN1 3374/4885MAPK1 3584/4885 |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | KMT2A 2611/4885MEN1 3374/4885MAPK1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.